Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

540 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-14

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the current study is to perform a unified, homogeneous data collection protocol that includes a large cohort of patients undergoing different treatment options for Major Depressive Disorder (MDD) as an avenue for investigating optimal biomarkers for depression treatments on an individual patient level.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Precision Medicine in the Depression Treatment

NCT05616559

Depressive Disorder, Major Treatment Outcome Cognitive Dysfunction +2 more

RECRUITING

Action Tendencies and Prognosis in Major Depressive Disorder

NCT04593537

Major Depressive Disorder

COMPLETED

Multimodal Differences in Effort-based Decision-Making in Depression

NCT06648460

Depression Anhedonia

NOT_YET_RECRUITING NA

Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression

NCT01579942

Major Depressive Disorder

TERMINATED

Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis

NCT02330679

Major Depressive Disorder

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketamine

Adult participants starting ketamine treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).

fNIRS measurement

Intervention Type OTHER

Kernel Flow2 measurements.

SPRAVATO

Adult participants starting SPRAVATO treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).

fNIRS measurement

Intervention Type OTHER

Kernel Flow2 measurements.

TMS

Adult participants starting TMS treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).

fNIRS measurement

Intervention Type OTHER

Kernel Flow2 measurements.

Antidepressants

Adult participants starting antidepressant treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment and short-term efficacy visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).

fNIRS measurement

Intervention Type OTHER

Kernel Flow2 measurements.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fNIRS measurement

Kernel Flow2 measurements.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Ketamine cohort

* Adult between the ages of 18 - 65, inclusive at time of enrollment
* Primary diagnosis of MDD as defined by DSM-5
* Determined by clinic to be eligible for ketamine treatment and agrees to receive ketamine treatment
* Agrees to start ketamine treatment in conjunction with study participation to capture pre-treatment measurements accurately
* Has not received a ketamine treatment course in the past 12 months
* Has not received a TMS treatment course in the past 3 months
* Ability to consent for themselves
* Fluency in English (speaking and reading)

SPRAVATO cohort

* Adult between the ages of 18 - 75, inclusive at time of enrollment
* Primary diagnosis of MDD as defined by DSM-5
* Determined by clinic to be eligible for SPRAVATO treatment and agrees to receive SPRAVATO treatment
* Agrees to start SPRAVATO treatment in conjunction with study participation to capture pre-treatment measurements accurately
* Has not received a ketamine or SPRAVATO treatment course in the past 12 months
* Has not received a TMS treatment course in the past 3 months
* Ability to consent for themselves
* Fluency in English (speaking and reading)

TMS cohort

* Adult between the ages of 18 - 65, inclusive at time of enrollment
* Primary diagnosis of MDD as defined by DSM-5
* Determined by clinic to be eligible for TMS treatment and agrees to receive TMS treatment
* Agrees to start TMS treatment in conjunction with study participation to capture pre-treatment measurements accurately
* Has not received a TMS treatment course in the past 12 months
* Has not received a ketamine or SPRAVATO treatment course within the last 3 months
* Ability to consent for themselves
* Fluency in English (speaking and reading)

Antidepressants cohort

* Adult between the ages of 18 - 65, inclusive at time of enrollment
* Primary diagnosis of MDD as defined by DSM-5
* Determined by clinic to be eligible for antidepressant treatment and agrees to receive antidepressant treatment
* Agrees to start antidepressant treatment in conjunction with study participation to capture pre-treatment measurements accurately
* Has not taken antidepressants in the past 3 months
* Has not received a TMS, SPRAVATO, or ketamine treatment course in the past 3 months
* Ability to consent for themselves
* Fluency in English (speaking and reading)

Exclusion Criteria

* Is or may be pregnant (for participant of childbearing potential \[POCBP\]), even if they have been cleared to receive the depression treatment
* Unable or unwilling to wear the TD-fNIRS headset
* Has had ECT in the past 3 months
* Major visual or auditory deficits that would prevent study task completion
* Hospitalizations and/or unstable health/medical condition/treatment in the last 30 days
* Major medical illnesses and psychiatric conditions including:

* Alzheimer's/Mild Cognitive Impairment
* Parkinson's disease
* Motor neuron diseases
* Multiple Sclerosis
* Brain Tumor
* Stroke
* Encephalitis
* Meningitis
* Epilepsy
* TBI with serious results (coma, unconscious for \>2 hrs, or skull fracture)
* Current serious psychiatric conditions (bipolar disorder, schizophrenia, or psychosis)
* Any other clinically significant medical condition or circumstance that, in the opinion of the Investigator, could affect patient safety, preclude evaluation of response, interfere with the ability to comply with study procedures, or prohibit completion of the study
* Not an appropriate candidate for the study in the judgment of the investigator(s)

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No